亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Anti-infectives targeting Gram-negative 'superbugs'

總結: New-generation polymyxins that target multidrug-resistant Gram-negative bacteria. The lead candidate novel lipopeptide antibiotic is in advanced preclinical development and has demonstrated superior in vivo efficacy and safety over currently used polymyxin antibiotics.

技術優勢: - Novel lipopeptide antibiotics targeting multidrug-resistant Gram-negative bacteria
- Greater efficacy (particularly against lung infections) and significantly less nephrotoxicity in animal models than currently available antibiotics
- Identified lead candidate that is amenable to scale-up manufacturing and ready for IND-enabling studies
- Potential for administration via intravenous, inhaled or topical routes

技術應用: - Multidrug resistant MDR gram-negative bacteria
- Infection
- Superbugs'
- Last-line antibiotics

詳細技術說明: Using their polymyxin drug discovery platform, researchers from the Monash University have identified a series of proprietary polymyxin analogues that are active against Gram-negative ‘superbugs’.
In vivo efficacy and toxicity studies in rodents demonstrate that, compared with polymyxin B and colistin, the lead candidate lipopeptide can be safely dosed at higher levels to achieve significantly improved efficacy against infections, particularly pneumonia, with significantly less nephrotoxicity.

其他: Monash University has extensive academic and industrial experience in medicinal chemistry, pharmacokinetics/ pharmacodynamics, and in vitro and in vivo evaluations of antibiotics. Monash seeks a partner to complete advanced IND-enabling preclinical assessment of its lead candidate lipopeptide and to undertake clinical development.

欲了解更多信息，請點擊這裡